Packer M - Search Results

1

Deleterious effects of hydralazine in patients with pulmonary hypertension.

Packer M, Greenberg B, Massie B, Dash H. Packer M, et al. N Engl J Med. 1982 Jun 3;306(22):1326-31. doi: 10.1056/NEJM198206033062203. N Engl J Med. 1982. PMID: 7070457

2

Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure.

Massie BM, Packer M, Hanlon JT, Combs DT. Massie BM, et al. Among authors: packer m. J Am Coll Cardiol. 1983 Aug;2(2):338-44. doi: 10.1016/s0735-1097(83)80172-7. J Am Coll Cardiol. 1983. PMID: 6345633 Free article.

3

Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure.

Packer M, Meller J, Medina N, Yushak M, Gorlin R. Packer M, et al. N Engl J Med. 1982 Jan 14;306(2):57-62. doi: 10.1056/NEJM198201143060201. N Engl J Med. 1982. PMID: 7053487

4

Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study.

Packer M, Narahara KA, Elkayam U, Sullivan JM, Pearle DL, Massie BM, Creager MA. Packer M, et al. J Am Coll Cardiol. 1993 Jul;22(1):65-72. doi: 10.1016/0735-1097(93)90816-j. J Am Coll Cardiol. 1993. PMID: 8509565 Free article. Clinical Trial.

5

Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: experience from trials of flosequinan.

Massie BM, Shah NB, Pitt B, Packer M. Massie BM, et al. Among authors: packer m. Am Heart J. 1996 Jul;132(1 Pt 1):130-6. doi: 10.1016/s0002-8703(96)90401-9. Am Heart J. 1996. PMID: 8701855 Clinical Trial.

6

Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial.

Massie B, Bourassa M, DiBianco R, Hess M, Konstam M, Likoff M, Packer M. Massie B, et al. Among authors: packer m. Circulation. 1985 May;71(5):963-71. doi: 10.1161/01.cir.71.5.963. Circulation. 1985. PMID: 3886191 Clinical Trial.

7

Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival.

Massie BM, Armstrong PW, Cleland JG, Horowitz JD, Packer M, Poole-Wilson PA, Rydén L. Massie BM, et al. Among authors: packer m. Arch Intern Med. 2001 Jan 22;161(2):165-71. doi: 10.1001/archinte.161.2.165. Arch Intern Med. 2001. PMID: 11176729 Clinical Trial.

8

Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group.

Gradman A, Deedwania P, Cody R, Massie B, Packer M, Pitt B, Goldstein S. Gradman A, et al. Among authors: packer m. J Am Coll Cardiol. 1989 Sep;14(3):564-70; discussion 571-2. doi: 10.1016/0735-1097(89)90093-4. J Am Coll Cardiol. 1989. PMID: 2768707 Free article.

9

Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure.

Packer M, Meller J, Medina N, Gorlin R, Herman MV. Packer M, et al. N Engl J Med. 1980 Jul 31;303(5):250-5. doi: 10.1056/NEJM198007313030503. N Engl J Med. 1980. PMID: 7383109

10

Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).

Massie BM, Berk MR, Brozena SC, Elkayam U, Plehn JF, Kukin ML, Packer M, Murphy BE, Neuberg GW, Steingart RM, et al. Massie BM, et al. Among authors: packer m. Circulation. 1993 Aug;88(2):492-501. doi: 10.1161/01.cir.88.2.492. Circulation. 1993. PMID: 8339411 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,092 results

Search Page

Filters